Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avastin Takes One Step Forward, One Step Back At ASCO

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech’s bevacizumab was the subject of one study supporting use in cervical cancer and one failing to show an effect in first-line brain cancer. A separate study repeated the disappointing brain cancer results, but the sponsor sees a silver lining in the quality of life dataset.

You may also be interested in...



China, Emerging Markets In Focus For Genentech On Broad Avastin Access In Cervical Cancer

U.S. FDA approval is fifth indication for Roche/Genentech’s Avastin. The number of cases in the U.S. is low and set to decline with better prevention, but disease is still considered a major global health problem.

Genentech Aims For Broad Access To Avastin In Cervical Cancer, But Needs To Figure Out How To Get There

FDA approval is fifth indication for Roche/Genentech’s Avastin. Number of cases in the U.S. is low and set to decline with better prevention, but disease is considered a major global health problem.

Avastin QoL Data In First-Line Glioblastoma Muddy Expansion Plans

Genentech’s bevacizumab was associated with improved maintenance of baseline quality of life and performance status in a confirmatory trial conducted under accelerated approval, but an NCI-funded study found higher rates of neurocognitive decline, increased symptom severity and decline in health-related quality of life.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel